Burkholderia mallei and Burkholderia pseudomallei: The causative micro-organisms of glanders and melioidosis

Recent Patents on Anti-Infective Drug Discovery

Volumn 2, Issue 3, 2007, Pages 233-241

  Gilad, Jacob ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Bioterrorism; Burkholderia; Glanders; Melioidosis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; COTRIMOXAZOLE; DOXYCYCLINE; DROTRECOGIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SULPERAZON; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BIOLOGICAL WARFARE; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISASTER PLANNING; DRUG EFFICACY; EPIDEMIOLOGY; GEOGRAPHIC DISTRIBUTION; HORSE DISEASE; HUMAN; MEDICAL RESEARCH; MELIOIDOSIS; MONOTHERAPY; NONHUMAN; PATENT; PATHOGENESIS; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SEPSIS; WESTERN HEMISPHERE;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOTERRORISM; BURKHOLDERIA MALLEI; BURKHOLDERIA PSEUDOMALLEI; CIVIL DEFENSE; GLANDERS; HORSE DISEASES; HORSES; HUMANS; MELIOIDOSIS; PATENTS AS TOPIC;

EID: 36749103353     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489107782497335     Document Type: Review

References (101)

1. Yabuuchi E, Kosako Y, Oyaizu H, et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992; 36: 1251-1275.
2. Dance DA. Melioidosis: The tip of the iceberg? Clin Microbiol Rev 1991; 4: 52-60.
3. Currie BJ. Burkholderia pseudomallei and Burkholderia mallei: Melioidosis and Glanders. In: Mandell G, Bennet JE, Dolin R (eds.). Principles and Practice of Infectious Diseases. New York City: Churchill Livingstone, 6th ed., 2005; 2622-2632.
4. Wheelis M. First shots fired in biological warfare. Nature. 1998; 395: 213
5. United States Medical Research Institute of Infectious Diseases USAMRIID's medical management of biological casualties. 5th Ed. Fort Detrick, MD: USAMRIID, August 2004.
6. Centers for Disease Control and Prevention. Biological and Chemical Terrorism: Strategic Plan for Preparedness and Response. MMWR 2000; 49: 1-26.
7. Cheng AC, Currie BJ. Melioidosis: Epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005, 18: 383-416.
8. Currie BJ, Jacups SP. Intensity of rainfall and severity of melioidosis, Australia. Emerg Infect Dis 2003; 9: 1538-1542.
9. Suputtamongkol Y, Hall AJ, Dance DA, et al. The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. Int J Epidemiol 1994; 23: 1082-1090.
10. Trakulsomboon S, Vuddhakul V, Tharavichitkul P, Na-Gnam N, Suputtamongkol Y, Thamlikitkul V. Epidemiology of arabinose assimilation in Burkholderia pseudomallei isolated from patients and soil in Thailand. Southeast Asian J Trop Med Public Health 1999; 30: 756-759.
11. Wilson GS, Miles A. Topley and Wilson's Principles of Bacteriology, virology and immunity. London: Edward Arnold, 6th Ed., 1975; pp. 1855-1863.
12. Leelarasamee A. Diagnostic value of indirect hemagglutination method for melioidosis in Thailand. J Infect Dis 1985; 2: 213-214.
13. Strauss JM, Groves MG, Mariappan M, Ellison DW. Melioidosis in Malaysia. II. Distribution of Pseudomonas pseudomallei in soil and surface water. Am J Trop Med Hyg 1969; 18: 698-702.
14. Wuthiekanun V, Smith MD, Dance DA, White NJ. Isolation of Pseudomonas pseudomallei from soil in north-eastern Thailand. Trans R Soc Trop Med Hyg 1995; 89: 41-43.
15. Currie BJ, Fisher DA, Howard DM, Burrow JN. Neurological melioidosis. Acta Trop 2000; 74: 145-151.
16. White N J. Melioidosis. Lancet. 2003; 361: 1715-1722.
17. Vorachit M, Lam Y, Jayanetra P, Costerton JW. Resistance of Pseudomonas pseudomallei growing as a biofilm on silastic discs to ceftazidime and cotrimoxazole. Antimicrob Agents Chemother 1993; 37: 2000-2002.
18. Inglis TJ, Rigby P, Robertson TA, Dutton NS, Henderson M, Chang BJ. Interaction between Burkholderia pseudomallei and Acanthamoeba species results in coiling phagocytosis, endamebic bacterial survival, and escape. Infect. Immun 2000; 68: 1681-1686.
19. Holden MT, Titball RW, Peacock SJ, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci USA 2004; 101: 14240-14245.
20. Egan AM, Gordon DL. Burkholderia pseudomallei activates complement and is ingested but not killed by polymorphonuclear leukocytes. Infect Immun 1996; 64: 4952-4959.
21. Harley VS, Dance DA, Tovey G, McCrossan MV, Drasar BS. An ultrastructural study of the phagocytosis of Burkholderia pseudomallei. Microbios 1998; 94: 35-45.
22. Simpson AJ, Smith MD, Weverling GJ, et al. Prognostic value of cytokine concentrations (tumor necrosis factor alpha, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis. J Infect Dis 2000; 181: 621-625.
23. Desmarchelier PM, Dance DA, Chaowagul W, et al. Relationships among Pseudomonas pseudomallei isolates from patients with recurrent melioidosis. J Clin Microbiol 1993; 31: 1592-1596.
24. Chierakul W, Winothai W, Wattanawaitunechai C, et al. Melioidosis in 6 Tsunami survivors in Southern Thailand. Clin Infect Dis 2005; 41: 982-90.
25. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31: 981-986.
26. Suputtamongkol Y, Chaowagul W, Chetchotisakd P, et al. Risk factors for melioidosis and bacteremic melioidosis. Clin Infect Dis 1999; 29: 408-413.
27. Kanaphun P, Thirawattanasuk N, Suputtamongkol Y, et al. Serology and carriage of Pseudomonas pseudomallei: a prospective study in 1000 hospitalized children in northeast Thailand. J Infect Dis 1993; 167: 230-233.
28. Strauss JM, Alexander AD, Rapmund G, Gan E, Dorsey AE. Melioidosis in Malaysia III. Antibodies to Pseudomonas pseudomallei in the human population. Am J Trop Med Hyg 1969; 18: 703-707.
29. Godoy D, Randle G, Simpson AJ, et al. Multilocus sequence typing and evolutionary relationships among the causative agents of melioidosis and glanders, Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 2003; 41: 2068-2079.
30. Heng BH, Goh KT, Yap EH, Loh H, Yeo M. Epidemiological surveillance of melioidosis in Singapore. Ann Acad Med Singapore 1998; 27: 478-484.
31. Punyagupta, S. Melioidosis. Review of 686 cases and presentation of a new clinical classification, In: Punyagupta S, Sirisanthana T, Stapatayavong B (ed.). Melioidosis. Bangkok: Bangkok Medical Publisher, 1989; p. 217-229.
32. Berger SA. Meliodosis. In: Marrie TJ (Ed.). Community-acquired pneumonia. New York: Kluwer Academic/Plenum Publishers, 2001; 811-819.
33. Chodimella U, Hoppes WL, Whalen S, Ognibene AJ, Rutecki GW. Septicemia and suppuration in a Vietnam veteran. Hosp Pract. 1997; 32: 219-221.
34. Dance DA, Davis TM, Wattanagoon Y, et al. Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. J Infect Dis 1989; 159: 654-660.
35. Leelarasamec A. Recent development in melioidosis. Curr Opin Infect Dis 2004; 17: 131-136.
36. Gilligan PH, Lum G, Vandamme PAP, Whittier S. Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, comamonas, Delftia, Pandoraea, and Acidovorax. In: Murray P, et al. (eds.). Manual of Clinical Microbiology, 8th Edition, Washington DC: ASM Press, 2003; 729-748.
37. American Society for Microbiology. Sentinel laboratory guidelines for suspected agents of bioterrorism. Clinical Laboratory Bioterrorism Readiness Plan, 21, November 2005.
38. Tiangpitayakorn C, Songsivilai S, Piyasangthong N, Dharakul T. Speed of detection of Burkholderia pseudomallei in blood cultures and its correlation with the clinical outcome. Am J Trop Med Hyg 1997; 57: 96-99.
39. Walsh AL, Smith MD, Wuthiekanun V, et al. Prognostic significance of quantitative bacteremia in septicemic melioidosis. Clin Infect Dis 1995; 21: 1498-1500.
40. Limmathurotsakul D, Wuthiekanun V, Chierakul W, et al. Role and significance of quantitative urine cultures in diagnosis of melioidosis. J Clin Microbiol 2005; 43: 2274-2276.
41. Ashdown LR. An improved screening technique for isolation of Pseudomonas pseudomallei from clinical specimens. Pathology 1979; 11: 293-97.
42. Dance DA, Wuthiekanun V, Naigowit P, White NJ. Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. J Clin Pathol 1989; 42: 645-648.
43. Walsh AL, Wuthiekanun V, Smith MD, Suputtamongkol Y, White NJ. Selective broths for the isolation of Pseudomonas pseudomallei from clinical samples. Trans R Soc Trop Med 1995; 89: 124.
44. Wuthiekanun V, Suputtamongkol Y, Simpson JH, Kanaphun P, White NJ. Value of throat swab in diagnosis of melioidosis. J Clin Microbiol 2001; 39: 3801-3802.
45. Howard K, Inglis TJ. Novel selective medium for isolation of Burkholderia pseudomallei. J Chn Microbiol 2003; 41: 3312-3316.
46. Weyant RS, Moss CW, Weaver RE, et al. Identification of unusual pathogenic gram negative aerobic and facultatively anaerobic bacteria. Baltimore: Williams & Wilkins, 2nd ed. 1996.
47. Vaid MY, Munner MA, Naeem M. Studies on the incidence of glanders at Lahore. Pakistan Vet. J 1981; 1: 75.
48. Lowe P, Engler C, Norton R. Comparison of automated and nonautomated systems for identification of Burkholderia pseudomallei. J Clin Microbiol 2002; 40: 4625-27.
49. Inglis TJ, Chiang D, Lee GS, Chor-Kiang L. Potential misidentification of Burkholderia pseudomallei by API 20NE. Pathology 1998; 30: 62-64.
50. Glass MB, Popovic T. Preliminary evaluation of the API 20NE and RapID NF Plus systems for rapid identification of Burkholderia pseudomallei and B. mallei. J Clin Microbiol 2005; 43: 479-483.
51. Koh TH, Yong Ng LS, Foon Ho JL, Sng LH, Wang GC, Tzer Pin Lin RV. Automated identification systems and Burkholderia pseudomallei. J Clin Microbiol 2003; 41: 1809.
52. Lowe P, Haswell H, Lewis K. Use of various common isolation media to evaluate the new VITEK 2 colorimetric GN card for identification of Burkholderia pseudomallei. J Clin Microbiol 2006; 44: 854-856.
53. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med 2001; 345: 256-258.
54. Tiyawisutsri T, Peacock SJ, Langa S, et al. Antibodies from patients with melioidosis recognize Burkholderia mallei but not Burkholderia thailandensis antigens in the indirect hemagglutination assay. J Clin Microbiol 2005; 43: 48724874.
55. Wuthiekanun V, Desakorn V, Wongsuvan G, et al. Rapid immuno-fluorescence microscopy for diagnosis of melioidosis. Clin Diag Lab Immunol 2005; 12: 555-556.
56. Jesudason MV, Balaji V, Sirisinha S, Sridharan G. Rapid identification of Burkholderia pseudomallei in blood culture supernatants by a coagglutination assay. Clin Microbiol Infect 2005; 11: 925-936.
57. Pongsunk S, Thirawattanasuk N, Piyasangthong N, Ekpo P. Rapid identification of Burkholderia pseudomallei in blood cultures by a monoclonal antibody assay. J Clin Microbiol 1999; 37: 3662-3667.
58. Steinmetz I, Reganzerowski A, Brenneke B, Haussler S, Simpson A, White NJ. Rapid identification of Burkholderia pseudomallei by latex agglutimation based on an exopolysaccharide-specific monoclonal antibody. J Clin Microbiol 1999; 37: 225-228.
59. Wuthiekanun V, Anutagool N, White NJ, Sirisinha S. A Rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis. Am J Trop Med Hyg. 2002; 66: 759-761.
60. Bauernfeind A., Roller C, Meyer D, Jungwirth R, Schneider I. Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. J Clin Microbiol 1998; 36: 2737-2741.
61. Gee JE, Sacchi CT, Glass MB, et al. Use of 16S rRNA gene sequencing for rapid identification and differentiation of Burkholderia pseudomallei and B. mallei. J Clin Microbiol 2003; 41:4647-4654.
62. Thibault FM, Valade E, Vidal DR. Identification and discrimination of Burkholderia pseudomallei, B. mallei, and B. thailandensis by real-time PCR targeting type III secretion system genes. J Clin Microbiol 2004; 42: 5871-5874.
63. U'Ren JM, Van Ert MN, Schupp JM, et al. Use of a real-time PCR TaqMan assay for rapid identification and differentiation of Burkholderia pseudomallei and Burkholderia mallei. J Clin Microbiol 2005; 43: 5771-5774.
64. Varma-Basil M, El-Hajj H, Marras SAE, et al. Molecular beacons for multiplex detection of four bacteria bioterrorism agents. Clin Chem 2004; 50: 1060-1062.
65. Scholz C, Al Dahouk S, Eickhoff M, et al. Development ofa 5′-nuclease real-time PCR assay targeting fliP for the rapid identification of Burkholderia mallei in clinical samples. Clin Chem 2006; 52: 307-310.
66. Woo PC, Lau SK, Woo GY, et al. Seronegative bacteremic melioidosis caused by Burkholderia pseudomallei with ambiguous biochemical profile: Clinical importance of accurate identification by 16S rRNA gene and groEL gene sequencing. I Clin Microbiol 2003; 41: 3973-3977.
67. Uhich RL, Ulrich MP, Schell MA, Stanley KH, DeShazer D. Development of a polymerase chain reaction assay for the specific identification of Burkholderia mallei and differentiation from Burkholderia pseudomallei and other closely related Burkholderiaceae. Diag Microbiol Infect Dis 2006; 55: 37-45.
68. Inglis TJJ, Merritt A, Chidlow G, Aravena-Roman M, Harnett G. Comparison of Diagnostic Laboratory Methods for Identification of Burkholderia pseudomallei. J Clin Microbiol 2005; 43: 2201-2206.
69. Clinical Laboratory and Standards Institute. Performance standards for antimicrobial susceptibility testing. 16th Informational Supplement M100-S16. Wayne, PA: CLSI, 2006.
70. Heine HS, England MJ, Wang DM, Byrne WR. in vitro Antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrob Agents Chemother 2001; 45:2119-2121.
71. Jenney AW, Lum G, Fisher DA, Currie BJ. Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. Int J Antimicrob Agents 2001; 17: 109-113.
72. Cheung TK, Ho PL, Woo PC, Yuen KY, Chau KY. Cloning and expression of class A beta-lactamase gene blaA (BPS) in Burkholderia pseudomallei. Antimicrob Agents Chemother 2002; 46: 1132-1135.
73. Livermore DM, Chau PY, Wong AI, Leung YK. Beta-lactamase of Pseudomorias pseudomallei and its contribution to antibiotic resistance. J Antimicrob Chemother 1987; 20: 313-321.
74. Niumsup P, Wuthiekanun V. Cloning of the class D β-lactamase gene from Burkholderia pseudomallei and studies on its expression in ceftazidime-susceptible and -resistant strains. J Antimicrob Chemother 2002; 50: 445-455.
75. Godfrey AJ, Wong S, Dance DA, Chaowagul W, Bryan LE. Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase. Antimicrob Agents Chemother 1991; 35: 1635-1640.
76. Yamamoto T, Naigowit P, Dejsirilert S, et al. In vitro susceptibilities of Pseudomonas pseudomallei to 27 antimicrobial agents. Antimicrob Agents Chemother 1990; 34: 2027-2029.
77. Smith MD, Wuthiekanun V, Walsh AL, White NJ. in-vitro Activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother 1996; 37: 611-615.
78. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004; 54: 1134-1138.
79. Thamlikitkul V, Trakulsomboon S. in vitro Activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis. Antimicorb Agents Chemother 2006;50: 1555-1557.
80. Walsh AL, Smith MD, Wuthiekanun V, White NJ. Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: Evaluation of current treatment Antimicrob Agents Chemother 1995; 39: 2356-2358.
81. Samuel M, Ti TY. Interventions for treating melioidosis. The Cochrane Database of Systematic Reviews 2002, Issue 4. Art.No.: CD001263. DOI: 10.1002/14651858. CD001263.
82. Sookprance M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime phis cotrimoxazole with chloramphenicol plus doxycyclinc and cotrimoxazole for treatment of severe melioidosis. Antimicrob Agents Clicinother 1992; 36: 158-162.
83. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 23: 697-701.
84. Simpson AJ, Suputtamcingkol Y, Smith MD, et al. Comparison of imipenern and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999; 29: 381-387.
85. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19: 846-853.
86. Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38: 32-37.
87. Bossi P, Tegnell A, Baka A, et al. BICHAT guidelines for the clinical management of glanders and meliodosis and bioterrorism-related glanders and meliodosis. Euro Surveill 2004; 9: 12.
88. Maharjan B, Chantratita N, Vesaratchavest M, et al. Recurrent melioidosis in patients in Northeast Thailand is frequently due to reinfection rather than relapse. J Clin Microbiol 2005; 43: 6032-6034.
89. Chaowagul W, Chierakul W, Simpson AJ, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycychnc for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005; 49: 4020-4025.
90. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD. Antibiotic susceptibility of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004; 54: 1134-1138.
91. van den Berghe G. Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-1367.
92. Kenny DJ, Russell P, Rogers D, Eley M, Titball RW. In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother 1999; 43: 2773-2775.
93. Health Protection Agency (HPA) Centre for Infection. Interim Guidelines for Action in the Event of a Deliberate Release: Glanders & Melioidosis, January 2006.
94. Rusnak JM, Kortepeter MG, Hawley RJ, Boudreau E, Aldis J, Pittman PR. Management guidelines for laboratory exposures to agents of bioterrorism. J Occup Environ Med 2004; 46: 791-800.
95. Chanana, G., Ventura, D., Saunders, K, Fawzi, M.B.: US20070026080 (2007).
96. Gao, G., Wilson, J.M., Alvira, M.: US20077198952 (2007).
97. Holst, P. J., Thomsen, A.R., Christensen, J.P.: WO07062656 (2007).
98. Elvin, S.John., Healey, G.D., Williamson, E.D., Eyles, J.E., Smither, S.J., Sarkar-Tyson, M., Atkins, T.P., Nelson, M., Titball, R.W.: WO07036735 (2007).
99. Ulrich, R., Jeddeloh, J., Oyston, P.: US20040171020 (2004).
100. Harland, D.N., Atkins, H.S., Walker, N.J., Nelson, M., Atkins, T.P., Titball, R.W.: WO 06109071A3 (2006).
101. Gilad J, Harary I, Dushnitsky T, Schwartz D, Amsalem Y. Burkholderia mallei and Burkholderia pseudomallei as bioterrorism agents: National aspects of emergency preparedness. IMAJ 2007; 9: 499-503.